Osteologix Initiates Phase II Clinical Trial Of Investigational Drug For Osteoporosis
Thu, 07 Dec 2006 08:00 AM EST
... Osteologix Inc. (OTC Bulletin Board: OLGX) announced today that it has initiated a randomized, double-blind, placebo-controlled phase II clinical trial of NB S101, its investigational drug for osteoporosis. The primary endpoint of the study is the change in patients' bone resorption. [click link for full article] ...
Related Topics
- Clinical Trials
- Osteoporosis
- Tarceva
- Pharmacology
- Psychopharmacology
- Bevacizumab Injection
- Trastuzumab
- Drug Safety
- Prescription Drugs
- Drug Side Effects
- Nystatin and Triamcinolone
- Drug Abuse
- Drug Information
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Raloxifene
- Depression

Not Signed In -

